Leland Gershell's questions to Urogen Pharma Ltd (URGN) leadership • Q4 2024
Question
Leland Gershell of Oppenheimer questioned if the UGN-103 trial might be amended to include treatment-naive patients and asked about plans to share more data from pipeline programs like ICVB-1042 and UGN-301.
Answer
President and CEO Liz Barrett stated they will not amend the UGN-103 trial to ensure it remains comparable to the UGN-102 study for a smoother approval process. Chief Medical Officer Mark Schoenberg added that for ICVB-1042, IND-enabling studies are underway this year with substantive data likely next year. For UGN-301, he anticipates reporting durability data from the combination arms later this year.